SMARCA4 and lung carcinoma: In vitro and in vivo SMARCA4/A2-deficient ovarian and lung cancer models showed BETi mediated anti-proliferative effects, showing that SMARCA4/A2 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 4/2) may be used as biomarkers for BETi sensitivity [127].